Table 1.
Interleukin-1 receptor antagonist (IL-1Ra) levels in studies of population-derived cohorts.
| Population Cohort Study (Ref.) | N—Case/ Non-Case |
Female % | IL-1Ra Concentration (pg/mL) |
IL-1Ra Concentration, Non-Case/Healthy | |
|---|---|---|---|---|---|
| Whitehall II [17] | baseline T2DM cases/ non-cases |
335/2475 | 30/27 | 308 (CI95%: 293–323) |
248 (CI95%: 244–252) |
| Health2000 [28] | men with MetS/ metabolically healthy |
1034/1403 | 0 | 343 (247–456) |
268 (191–364) |
| Health2000 [28] | women with MetS/ metabolically healthy |
964/1859 | 100 | 402 (272–570) |
306 (213–423) |
| FINRISK97 [28] | men with MetS/ metabolically healthy |
972/2499 | 0 | 284 (211–371) |
208 (159–267) |
| FINRISK97 [28] | women with MetS/ metabolically healthy |
666/2892 | 100 | 360 (255–458) |
240 (176–310) |
| Gutenberg Health Study [37] | prediabetes/ normoglycemia |
1425/12,152 | 52/50 | 351 (271–485) |
311 (233–408) |
| KORA F4 [36] | elderly polyneuropathy/ no polyneuropthy |
146/901 | 39/51 | 335 (248–472) |
304 (233–400) |
T2DM—type 2 diabetes; MetS—metabolic syndrome; IL-1Ra levels are shown as medians (interquartile range) unless indicated and means with 95% confidence intervals (CI 95%).